Mind + Muscle

technical minds + legal muscle


dig deep

4 Questions After Amgen-Sandoz Rehearing Bids Fizzle Out

  • 10.16.15
  • Paul A. Calvo, Ph.D.
  • Law360

Paul A. Calvo, Ph.D., is quoted in Law360's "4 Questions After Amgen-Sandoz Rehearing Bids Fizzle Out," discussing the Federal Circuit's panel decision to exempt biosimilar makers from exchanging intellectual property information with brand-name rivals, also known as "the patent dance."

"Something that is open is: If you do the patent dance, maybe you don't even need to provide notice of commercial marketing," said Calvo. "That's just hanging out there in the wind."

For more information regarding the Federal Circuit's decision, visit Law360.com.

Related People

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.